Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

• Autors principals: Christopher A. Seid (Autor), Kathryn M. Jones (Autor), Jeroen Pollet (Autor), Brian Keegan (Autor), Elissa Hudspeth (Autor), Molly Hammond (Autor), Junfei Wei (Autor), C. Patrick McAtee (Autor), Leroy Versteeg (Autor), Amanda Gutierrez (Autor), Zhuyun Liu (Autor), Bin Zhan (Autor), Jonathan L. Respress (Autor), Ulrich Strych (Autor), Maria Elena Bottazzi (Autor), Peter J. Hotez (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2017-03-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a standalone product or in combination with conventional...